Landmark approval for pancreatic cancer; Reactions to Lilly’s Phase 1 secrecy; and more

Welcome back to Endpoints Weekly! The big news this week was the FDA’s approval of Revolution Medicines’ pancreatic cancer treatment Rasonque. The drug stunned researchers and spurred excitement in April, when it nearly doubled patients’ ...